FP187

BRAND NAME: n/a GENERIC NAME: n/a EXPERIMENTAL/INTERNAL COMPANY NAME: FP187

TESTING PHASE II CLINICAL TRIALS CLICK HERE

DRUG USE (P OR PsA)	METHOD OF DELIVERY	DEVELOPING COMPANY/COMPANIES
Moderate to severe plaque psoriasis	Oral/pill	Forward Pharma

Description and Comments

According to the company, "FP187 is an oral small molecule that demonstrated promising pharmacokinetics and good tolerability in Phase I testing in healthy volunteers." Phase Two testing is being done in Germany by the company, headquartered in Copenhagen, Denmark.  Results are expected in the third quarter of 2011.

Other News and Links

Company news release, September 2010